Matinas BioPharma Provides Positive Outcomes Update on the MAT2203 Compassionate/Expanded Use Access Program, Including Multiple Patients with Complete Clinical Resolution
February 26, 2024 08:00 ET
|
Matinas BioPharma Holdings, Inc.
A total of 19 patients with serious/life-threatening invasive fungal infections have been enrolled, including aspergillosis, mucormycosis, fusarium, candidiasis, cryptococcosis, and endemic mycoses...
Matinas BioPharma Successfully Reaches Agreement with FDA for a Single Phase 3 Registration Trial to Support an NDA for MAT2203 for the Treatment of Invasive Aspergillosis
February 20, 2024 07:30 ET
|
Matinas BioPharma Holdings, Inc.
ORALTO Phase 3 trial focused on desired initial target indication of early oral step-down treatment of invasive aspergillosis infections in adults who have limited or no treatment options ...
Matinas BioPharma to Present at Biotech Showcase 2024
January 03, 2024 07:00 ET
|
Matinas BioPharma Holdings, Inc.
BEDMINSTER, N.J., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on redefining the intracellular delivery of small...
Matinas BioPharma Demonstrates in vivo Biological Activity and Disease Improvement in Two Inflammatory Disease Models with Oral LNC-Delivered Small Oligonucleotides
December 27, 2023 07:30 ET
|
Matinas BioPharma Holdings, Inc.
In an acute colitis model, data show statistically significant knockdown of elevated levels of serum TNFα, reductions in tissue TNFα mRNA and improvement in disease activity scores In an acute...
Matinas BioPharma Provides Update to MAT2203 Regulatory and Development Pathway Following Feedback from FDA
December 21, 2023 07:30 ET
|
Matinas BioPharma Holdings, Inc.
Written Preliminary Comments on the Phase 3 Registration Trial for MAT2203 Move Company Closer to Full Alignment with FDA Matinas to Meet with FDA Early in the First Quarter of 2024 to Finalize Phase...
Matinas BioPharma Reports Third Quarter 2023 Financial Results and Provides a Business Update
November 08, 2023 16:05 ET
|
Matinas BioPharma Holdings, Inc.
FDA feedback on MAT2203 Phase 3 program supports a patient population in invasive aspergillosis with limited treatment options, acknowledges potential for LPAD pathway; composite superiority endpoint...
Matinas BioPharma Announces Positive in vivo Efficacy Results of Oral LNC Docetaxel Formulation in a Melanoma Model
November 07, 2023 07:30 ET
|
Matinas BioPharma Holdings, Inc.
BEDMINSTER, N.J., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies...
Matinas BioPharma to Webcast Conference Call to Discuss Third Quarter 2023 Financial Results and Provide a Business Update on November 8, 2023
November 01, 2023 07:00 ET
|
Matinas BioPharma Holdings, Inc.
BEDMINSTER, N.J., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on redefining the intracellular...
Patient with Candida krusei Infection in Matinas BioPharma’s Oral MAT2203 Expanded Access Program Achieves Complete Clinical Resolution
October 11, 2023 07:30 ET
|
Matinas BioPharma Holdings, Inc.
BEDMINSTER, N.J., Oct. 11, 2023 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid...
Matinas BioPharma to Present at Two Investment Conferences in October 2023
September 28, 2023 07:00 ET
|
Matinas BioPharma Holdings, Inc.
BEDMINSTER, N.J., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on redefining the intracellular delivery of small...